04-01-02

Express Mail No.: EL 477 035 316 US

E#11/K.T.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Warrell et al.

RECEIVED

APR v 3 2002

Application No.: 09/709,170

Group Art Unit: 1635

TECH CENTER 1600/2900

Filed: November 10, 2000

Examiner: Mary Schmidt

For:

METHODS OF TREATMENT OF A BCL-2 Attorney Docket No.: 10412-025

DISORDER USING BCL-2 ANTISENSE

OLIGOMERS

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In response to the Office Communication mailed March 20, 2002 and the accompanying Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply"), Applicants submit herewith (1) copies of a Sequence Listing in paper and computer readable forms in connection with the above-identified application; and (2) return copy of Notice to Comply.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e) respectively, are the same. I hereby state that the submission herein under 37 C.F.R. § 1.821(g) does not include new matter.

It is estimated that no fee is required for this response. In the event that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date March 29, 2002

Kig No. 43,9 VUZZ i

Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, N.Y. 10036-2711

(212) 790-9090

Enclosures